Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation (Q34188814)

31 July 2017

title

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation (English)

1 reference

31 July 2017

main subject

Gram-negative bacteria

0 references

1 reference

1 reference

Nathan Paul Wiederhold

object named as

Nathan P Wiederhold

series ordinal

2

0 references

Christopher R Frei

series ordinal

1

object named as

Christopher R Frei

1 reference

31 July 2017

David S Burgess

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

4 February 2008

1 reference

31 July 2017

number of pages

8

1 reference

Journal of Antimicrobial Chemotherapy

inferred from page(s)

published in

1 reference

31 July 2017

volume

61

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

621-628

1 reference

Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Impact of pharmacodynamics on breakpoint selection for susceptibility testing

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics of ertapenem in healthy young volunteers.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Animal model pharmacokinetics and pharmacodynamics: a critical review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

What in vitro models of infection can and cannot do.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacology of ceftizoxime compared with that of cefamandole

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics of cefoperazone and tobramycin alone and in combination

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952740

Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Pharmacology of aztreonam after intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Continuous infusion beta-lactams for intensive care unit pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM536

Prevention of resistance: a goal for dose selection for antimicrobial agents

21 January 2018

1 reference

12 December 2020

The pharmacodynamics of beta-lactams

1 reference

12 December 2020

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

1 reference

12 December 2020

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

1 reference

12 December 2020

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily

1 reference

12 December 2020

The pharmacodynamics of aminoglycosides

1 reference

12 December 2020

Identifiers

DOI

10.1093/JAC/DKM536

1 reference

31 July 2017

1 reference

31 July 2017

1 reference